Q32 Bio

Q32 Bio is a clinical-stage biotechnology firm focused on developing biologic therapeutics to restore immune homeostasis in patients with autoimmune and inflammatory diseases. The company was initially founded as AdMIRx Inc. in 2017 by Shelia Violette, Ph.D., a scientific leader with over two decades of experience in inflammation and autoimmunity, and David Grayzel, an Atlas Venture partner. The company rebranded to Q32 Bio Inc. in April 2020. A significant milestone occurred in March 2024, when Q32 Bio completed a reverse merger with Homology Medicines, gaining a NASDAQ listing under the ticker "QTTB". This transaction, coupled with a concurrent $42 million private placement, provided the company with approximately $130 million in capital, extending its financial runway to mid-2026.

The company's business model is centered on the clinical development and potential commercialization of its therapeutic candidates that target potent regulators of both the innate and adaptive immune systems. Its strategy involves advancing its pipeline through rigorous clinical trials to address significant unmet medical needs in the autoimmune space. Q32 Bio operates by targeting specific immune pathways to re-balance immune function rather than employing broad immunosuppression. The company’s pipeline is built on two main programs. The first is focused on the adaptive immune system with its lead candidate, bempikibart (formerly ADX-914). The second program targets the innate immune system via its tissue-targeted complement regulation platform, which produced the ADX-097 candidate.

Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking signaling from both IL-7 and TSLP, pathways implicated in various T-cell-mediated autoimmune diseases. It is being evaluated in Phase 2 clinical trials for the treatment of alopecia areata (AA) and atopic dermatitis (AD). The company's other key candidate, ADX-097, is engineered for tissue-targeted regulation of the complement system. This approach is designed to inhibit complement activation directly at the site of disease, avoiding the long-term systemic blockade associated with current complement therapies. Following a strategic restructuring to extend its cash runway, Q32 Bio has prioritized the development of bempikibart for alopecia areata while discontinuing the ADX-097 program.

Keywords: Q32 Bio, clinical-stage biotechnology, autoimmune diseases, inflammatory diseases, immune homeostasis, biologic therapeutics, bempikibart, ADX-914, alopecia areata, atopic dermatitis, adaptive immunity, IL-7Rα antibody, TSLP pathway, reverse merger, Homology Medicines, QTTB, ADX-097, complement system, tissue-targeted regulation, innate immunity, Shelia Violette, drug development, immunology